Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
June 13, 2024 06:38 ET
|
ADALVO LIMITED
Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
June 13, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
June 05, 2024 08:30 ET
|
GlucoTrack, Inc.
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet...
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024 06:45 ET
|
MannKind
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS
Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications
May 24, 2024 03:00 ET
|
Atrogi
STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of...
UMeWorld Limited Invites Investors to Upcoming Webinar, June 4th at 12PM EST Hosted by CEO Michael Lee to Discuss the Upcoming Acquisition and Relocation
May 23, 2024 08:00 ET
|
UMeWorld Limited
UMeWorld Limited Invites Investors to Upcoming Webinar
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
May 21, 2024 08:00 ET
|
Y-Prime, LLC
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
May 20, 2024 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
UMeWorld Announces Strategic Expansion in the U.S. and Forecasts Significant Revenue Growth
May 16, 2024 08:00 ET
|
UMeWorld Limited
HONG KONG, May 16, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTCPK: UMEWF) is pleased to announce a strategic plan for expansion in the United States. Having secured proprietary enzymatic...